Want to join the conversation?
$EMR expects difficult conditions to persist in its served markets during FY16. These market conditions were anticipated and have not changed $EMR's view of its financial objectives that were developed heading into 2016. Underlying sales for 2016 are still expected to be down about 2-5% and reported sales are likely to be down about 6-9%.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.